Volume 25, Issue 2 (7-2022)
jha 2022, 25(2): 45-61 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Pour Asghari H, Saadati M, Moradi N, Rezapour A, Yousefzadeh N, Dehnad A et al . Policy Analysis of Allocating the Subsidized Currency to Medication in Iran and Development of Political Alternatives. jha 2022; 25 (2) :45-61
URL: http://jha.iums.ac.ir/article-1-4122-en.html
URL: http://jha.iums.ac.ir/article-1-4122-en.html
Hamid Pour Asghari1 
, Maryam Saadati2 , Najmeh Moradi3 , Aziz Rezapour4 , Negar Yousefzadeh2 , Afsaneh Dehnad5 , Jalal Arabloo 6
, Maryam Saadati2 , Najmeh Moradi3 , Aziz Rezapour4 , Negar Yousefzadeh2 , Afsaneh Dehnad5 , Jalal Arabloo 6
1- Assistant Professor, Hospital Management Research Center, Iran University of Medical Sciences, Tehran
2- Ph.D. student, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran
3- Assistant Professor, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran
4- Associate Professor, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran
5- Professor, School of Health Management & Information Sciences, Iran University of Medical Sciences, Tehran
6- Assistant Professor, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran , arabloo.j@iums.ac.ir
2- Ph.D. student, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran
3- Assistant Professor, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran
4- Associate Professor, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran
5- Professor, School of Health Management & Information Sciences, Iran University of Medical Sciences, Tehran
6- Assistant Professor, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran , arabloo.j@iums.ac.ir
Abstract: (1201 Views)
Introduction: The pharmaceutical industry of each country shows the capability of that country in providing health for the society. Medication has always been one of the most important pillars of health due to its effects on health. As a result, production, distribution, and pricing are a special priority of governments. Therefore, the medication subsidized currency allocation policy was formulated and implemented in order to guarantee patients' access to drugs in the conditions of currency shortage and international sanctions against Iran. The objectives of the present study were to analyze the policy of subsidized currency allocation to medication and to present political alternatives in Iran.
Methods: The present study is a retrospective health policy analysis using a qualitative research method. Data were collected by using semi-structured interviews with key informants through analyzing policy and legal documents. We also analyzed the data by using framework analysis. To categorize and analyze the findings, we used MAXQDA 11 software.
Results: Results showed that contextual factors, including situational, structural, cultural, and international factors had an impact on all policy-making processes of currency allocation for medication. Four political alternatives for the allocation of subsidized currency for medication, we proposed: 1) removing the policy of subsidized currency and paying the exchange rate difference to insurance companies; 2) announcing a new rate for the subsidized currency; 3) paying the total exchange rate difference (selling half of the currency to pharmaceutical industries and the rate difference to consumers); 4) releasing a part of medication currency.
Conclusion: Challenges and negative consequences of subsidized currency have gradually emerged. Before modifying the policy of subsidized currency, the requirements should be reviewed. Developing a detailed and step-by-step road map via the participation of influential and interested institutions is necessary to modify this policy.
Methods: The present study is a retrospective health policy analysis using a qualitative research method. Data were collected by using semi-structured interviews with key informants through analyzing policy and legal documents. We also analyzed the data by using framework analysis. To categorize and analyze the findings, we used MAXQDA 11 software.
Results: Results showed that contextual factors, including situational, structural, cultural, and international factors had an impact on all policy-making processes of currency allocation for medication. Four political alternatives for the allocation of subsidized currency for medication, we proposed: 1) removing the policy of subsidized currency and paying the exchange rate difference to insurance companies; 2) announcing a new rate for the subsidized currency; 3) paying the total exchange rate difference (selling half of the currency to pharmaceutical industries and the rate difference to consumers); 4) releasing a part of medication currency.
Conclusion: Challenges and negative consequences of subsidized currency have gradually emerged. Before modifying the policy of subsidized currency, the requirements should be reviewed. Developing a detailed and step-by-step road map via the participation of influential and interested institutions is necessary to modify this policy.
Type of Study: Research |
Subject:
Health Policy
Received: 2022/04/1 | Accepted: 2022/06/21 | Published: 2022/11/12
Received: 2022/04/1 | Accepted: 2022/06/21 | Published: 2022/11/12
References
1. Kale D. From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the indian pharmaceutical industry. Technol Forecast Soc Change. 2019;145:370-83. [DOI:10.1016/j.techfore.2018.09.020]
2. Kale D. The distinctive patterns of dynamic learning and inter‐firm differences in the Indian pharmaceutical industry. Br J Manag. 2010;21(1):223-38. [DOI:10.1111/j.1467-8551.2009.00651.x]
3. Andayesh Y, Keshavarz Kh, Zahiri M, Mirian I, Beheshti A, Imani A, et al. The effects of drug subsidies exclusion on price index of sectors and household's expenditures using structural path analysis. Journal of health administration. 2011;13(42):45-56. [In persian]
4. Barouni M, Jalaei A, Jafari Sh. The effect of exchange rate uncertainty on import of medical and pharmaceutical products in Iran. Health and Development Journal. 2016;5(1):13-23.
5. Zarei L, Yousefi N, Azmand S, Joulaei H, Bagheri Lankarani K. The challenges of stopping dual exchange rate in pharmaceutical products and its correction effects in Iran. Iranian Journal of culture and Health Promotion. 2022;5(4):537-42.
6. Afsharmanesh G, Rahimi F, Zarei L, Peiravian F, Mehralian Gh. Public and decision-maker stated preferences for pharmaceutical subsidy decisions in Iran: An application of the discrete choice experiment. J Pharmaceut Pol Pract. 2021;14(1):1-7. [DOI:10.1186/s40545-021-00365-0]
7. Kaviani Z, Sadegi N, Shahbazian A, Abdollahi M. Preferred currency alternative protection policy. Tehran: Islamic Parliament Research Center of The Islamic Republic of Iran, 2019. 47 p. Report No.: 16430.
8. Amin-Tahmasbi H, Asgharpour M, Izdiar P. Evaluation of the government's support policies for the pharmaceutical industry in the midst of sanctions and the covid-19 pandemic. Journal of health administration. 2022;25(1):69-79. [In persian] [DOI:10.52547/jha.25.1.69]
9. Kaviani Z, Abdollahi M. Expert opinion on: "Plan to allocate currency with a preferential rate to basic goods". Tehran: Islamic Parliament Research Center of The Islamic Republic of Iran ,2019. 21 p. Report No.: 17311.
10. Fan, Emma Xiaoqin. A note on dual/multiple exchange rates. Philippines: Asian Development Bank; 2004. 14 p. Report No.: 26.
11. Jafari M, Rezaeizadeh MJ, Abasi B. A study of the rules and regulations of distribution and pricing of the Iranian pharmaceutical system from the perspective of the right to health. Teb va tazkiye. 2021;29(4):296-310.
12. Buse K, Mays N, Walt G. Making health policy. 2nd ed. Maidenhead: Mcgraw-hill education; 2012.
13. Hackett A, Strickland K. Using the framework approach to analyse qualitative data: A worked example. Nurse Res. 2018;26(2):8-13. [DOI:10.7748/nr.2018.e1580]
14. Franklin C, Cody PA, Ballan M. Reliability and validity in qualitative research. The handbook of social work research methods. 2nd ed. London: SAGE; 2010. [DOI:10.4135/9781544364902.n19]
15. Minayo MCS. Qualitative analysis: Theory, steps and reliability. Cien Saude Colet. 2012;17(3):621-6. [DOI:10.1590/S1413-81232012000300007]
16. Islamic Parliament Research Center of The Islamic Republic of Iran. Approval of the letter regarding the action of the central bank of the islamic republic of iran regarding the provision of foreign exchange for goods listed in group 1 (including basic and essential goods, medicine and medical equipment). Tehran: Islamic Parliament Research Center of The Islamic Republic of Iran; 2018. 2 p. Report No.: 21383.
17. Budget law of the islamic republic of iran. 2018. [In persian]
18. Karimi M, Haghpanah S. The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran. Health Policy. 2015;119(2):239-43. [DOI:10.1016/j.healthpol.2014.12.011]
19. Abhari B, Aleemran R, Aghajani H. The long-run effect of sanctions on the central bank of islamic republic of Iran on health: An autoregressive distributed lags approach. Journal of health administration. 2021;24(1):98-109. [In persian] [DOI:10.52547/jha.24.1.98]
20. Abhari B, Aleemran R, Aghajani H. The effect of sanctions on Iran's health system using provincial data and spatial panel methods from 2009 to 2016. Journal of health administration. 2020; 23(1):58-73. [In persian] [DOI:10.29252/jha.23.1.58]
21. Shahabi Sh, Fazlalizadeh H, Stedman J, Chuang L, Shariftabrizi A, Ram R. The impact of international economic sanctions on iranian cancer healthcare. Health Policy. 2015;119(10):1309-18. [DOI:10.1016/j.healthpol.2015.08.012]
22. Hosseini A. Impact of sanctions on procurement of medicine and medical devices in Iran; a technical response. Arch Iran Med. 2013;16(12):736-8.
23. Davari M, Walley T, Haycox A. Pharmaceutical policy and market in iran: Past experiences and future challenges. J Pharmaceut Health Serv Res. 2011;2(1):47-52. [DOI:10.1111/j.1759-8893.2011.00042.x]
24. Yousefi N, Moradi N, Dinarvand R, Ghiasi G, Inanloo H, Peiravian F. Policies to improve access to pharmaceutical products in shortage: The experience of Iran food and drug administration. Daru. 2019;27(1):169-77. [DOI:10.1007/s40199-019-00259-2]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Site Keywords
Health, Administration, Scientific Article, Iran University of Medical Sciences,
